Summary:
Sun Pharma's Assam eye-care manufacturing halt poses limited estimated revenue exposure but raises broader quality concerns. Q2 FY27 revenue grew 12%, while reported profit fell 36% due to one-time charges. Investors await regulatory clearance, company clarification and restart details.
Eye care is only about 1% of Sun Pharma's sales. What investors are really pricing is whether the Assam quality problem stays contained.
Sun Pharma is in the spotlight after a Reuters report that Indian drug regulators ordered it to stop making eye-care products at its plant in Assam. The stock exchange has asked the company to clarify the story. According to the report, the Central Drugs Standard Control Organisation (CDSCO) and the Assam drugs controller gave the order on 20 August, after inspectors found the plant's quality management system falling short. It only came out on 30 October, the day Sun Pharma (NSE: SUNPHARMA) posted its Q2 FY27 numbers.
Read the headline and it sounds bad. The money is small, though. Eye care makes up about 3% of Sun Pharma's domestic revenue, which on our rough maths is around 1% of group sales. The bigger worry is trust. Sun Pharma wants to close its $11.75 billion Organon deal, and the US Food and Drug Administration (FDA) stopped shipments from its Halol plant last year. A second site in trouble makes people ask how closely quality is watched across all its factories. We have not seen the company's reply to the exchange, so we have relied on press reports and the earnings call.
Sun Pharma Assam Plant Halt: Timeline of Events From Recall to Exchange Query
Regulators and a medical body acted well before the news became public, so the order of events matters.
| Date (2026) | Event |
| June | All India Ophthalmological Society warns that some Predmet eye-drop batches appear contaminated after infection cases; Sun Pharma recalls Predmet |
| July | Sun Pharma voluntarily recalls about 11 eye-care brands; regulators seek details on 332 batches |
| 10 August | Show-cause notice over quality management system failures |
| 20 August | CDSCO and the Assam drugs controller halt manufacture, sale and distribution of ophthalmic products from the Kokjhar plant until a compliance report is accepted |
| 30 October | Reuters reports the order; management confirms the recall and a temporary cessation on its results call but declines to comment on the order |
| 4 November | Exchange seeks clarification from Sun Pharma on the news item |
Reports leave a few things unanswered. Nobody has said whether every recalled product was actually contaminated, whether any went abroad, or whether patients were hurt. Reuters could not confirm either that the 332 batches regulators asked about all belong to the 11 named brands.
Sun Pharma's position, from the earnings call and statements, comes down to this:
· It describes the stop as voluntary: management said it "voluntarily initiated a temporary cessation" and informed the regulators.
· A compliance report has been filed and is under review, according to an unnamed official quoted by Reuters.
· Remedial action is under way.
· No restart date has been given, and management declined to comment on the regulator's order.
Sun Pharma Q2 FY27 Results: Profit Fell 36% on One-Time Charges While Sales Rose 12%
Sun Pharma's reported profit fell sharply, but almost all of the fall comes from one-off charges. Adjusted profit, which leaves them out, rose 1%.
| Consolidated (₹ Cr) | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
| Revenue from operations | 16,199 | 14,478 | +12% | 15,300 | +6% |
| Operating profit (EBITDA) | 4,744 | 4,527 | +5% | 4,418 | +7% |
| Operating margin | 29.3% | 31.3% | 28.9% | ||
| Reported net profit | 1,989 | 3,118 | -36% | 2,895 | -31% |
| Adjusted net profit | 3,162 | 3,118 | +1% |
· ₹923 crore tied to a September settlement in US generic drug pricing antitrust litigation, including legal costs.
· ₹346 crore of Organon deal costs.
· A ₹95 crore tax benefit offset part of the charge.
One report describes the charge as mostly Organon costs and labour code provisions, so the breakdown differs by source. The total is the same in both, and we use the breakdown from the more detailed report. Operating earnings grew modestly. EBITDA rose 5% to ₹4,744 crore, but the margin slipped to 29.3% from 31.3% because Q2 FY26 benefited from sales of lenalidomide, a cancer drug whose US sales have since fallen.
How Much Does the Halt Hurt? India Sales, Eye-Care Exposure and the US Business
The halt order is dated 20 August, so the September quarter already includes roughly six weeks of it. India formulations sales still grew 17% to ₹5,552 crore, and market share rose to 8.6% from 8.3%. That is our reading, not a company statement, because Sun Pharma has not published an ophthalmology revenue figure. The bigger pressure on earnings sits in the US, not Assam:
· US sales were $455 million, down 8.2% from a year ago, mainly from lenalidomide erosion, and about 27% of group sales.
· Sales of Ilumya, a psoriasis drug, grew more slowly in the US, which management blamed on a mix of market and execution issues.
· Emerging markets grew 7.6% to $350 million, and specialty medicines grew 6.9% to $356 million.
No US recall of the eye-care products has been reported. The Assam site matters more for the future than the present, because Sun Pharma had said it was expected to become one of its largest sterile manufacturing hubs, and a delay pushes that capacity out.
Temporary Setback or Structural Quality Problem? What Decides the Answer
Whether this is temporary depends mostly on the regulator and on what inspectors found elsewhere in the company.
It looks contained if:
· Regulators sign off on the compliance report and the eye-drop lines restart within a few months.
· Management can show the fixes cover the whole quality system, not one production line.
· Nothing similar turns up at another plant before Organon closes.
It looks structural if:
· The review drags on, or inspectors ask for more fixes.
· More recalls or patient-safety reports surface.
· The FDA or another overseas regulator ties the findings to plants that supply export markets.
Sun Pharma Valuation After the Eye-Care News: What ₹1,783 and 34.8x Earnings Already Price In
On 3 November Sun Pharma traded near ₹1,783, a market value of about ₹4.28 lakh crore. That is 34.8 times trailing earnings and roughly 4.8 times book value (our calculation), with a yield of 0.9%. Return on capital employed is 20.5% and return on equity 16%. The stock actually rose about 2.7% to ₹1,808 during the session on 30 October, so investors looked past both the plant news and the profit fall. That fits the small revenue exposure. It also means the price carries no discount for a wider quality problem.
The balance sheet gives cover. Net cash was about $3.3 billion, and borrowings were ₹3,241 crore in September against ₹4,627 crore in March. The Organon deal is expected to close in the March 2027 quarter, and acquisition costs will continue until then. Research and development spending was 4.8% of sales against a 6 to 7% full-year target, so management expects a sharp rise in the second half. That could weigh on margins just when Organon debt costs begin.
Sun Pharma Catalysts to Watch After the Assam Halt
Four developments will tell investors more than the headline did:
· Sun Pharma's written reply to the exchange, including any figure for ophthalmology sales.
· The regulator's decision on the compliance report, and a restart date.
· India formulations growth in Q3 FY27, now that the halt covers a full quarter.
· Organon closing on schedule, and whether quality questions slow regulatory approvals.
Our view: this is a small revenue problem with a larger reputation risk. The business can absorb the loss of eye-care sales, and the stock behaves as if it can. What we cannot judge yet is how far the quality findings travel beyond Assam. We would wait for the company's reply and the regulator's decision before treating this as closed.
Disclaimer: This article is analytical commentary for informational purposes and is not personalised investment advice.
